Publicacions
-
Wiese M, Hamdan FH, Kubiak K, Diederichs C, Gielen GH, Nussbaumer G, Carcaboso AM, Hulleman E, Johnsen SA and Kramm CM.
Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells
CELL DEATH & DISEASE . 11(8): 673-673. Nº de cites: 40
-
Castillo H, Monterrubio C, Pascual-Pastó G, Gomez-Gonzalez S, Garcia-Dominguez DJ, Hontecillas-Prieto L, Resa-Parés C, Burgeño-Sandoval V, Paco-Mercader S, Gene-Olaciregui N, Vilà-Ubach M, Restrepo-Perdomo C, Cuadrado-Vilanova M, Balaguer-Lluna L, Pérez-Jaume S, Castañeda-Heredia A, Santa-María López V, Roldan-Molina M, Suñol M, de Alava E, Mora J, Lavarino C and Carcaboso AM.
Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution
JOURNAL OF CONTROLLED RELEASE . 324: 440-449. Nº de cites: 6
-
Chen KY, Bush K, Klein RH, Cervantes V, Lewis N, Naqvi A, Carcaboso AM, Lechpammer M and Knoepfler PS.
Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling
Communications Biology . 3(1): 363-363. Nº de cites: 32
-
Bossacoma F, Cuadrado-Vilanova M, Vinent-Genestar J, Correa MG, Gavrus D, Castillo H, Català-Mora J, Mora J, Schaiquevich P, Chantada G and Carcaboso AM.
Optimizing the storage of chemotherapeutics for ophthalmic oncology: stability of topotecan solution for intravitreal injection
OPHTHALMIC GENETICS . 41(4): 397-400. Nº de cites: 1
-
Fernández-Rodríguez J, Morales-La Madrid A, Gel B, Castañeda-Heredia A, Salvador-Hernandez H, Martínez-Iniesta M, Moutinho C, Morata J, Heyn H, Blanco I, Creus-Bachiller E, Capella G, Farré L, Vidal A, Soldado F, Krauel L, Suñol M, Serra E, Villanueva A and Lázaro C.
Use of patient derived orthotopic xenograft models for real-time therapy guidance in a pediatric sporadic malignant peripheral nerve sheath tumor
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY . 12: . Nº de cites: 5
-
Meel MH, de Gooijer MC, Metselaar DS, Sewing ACP, Zwaan K, Waranecki P, Breur M, Buil LCM, Lagerweij T, Wedekind LE, Twisk JWR, Koster J, Hashizume R, Raabe EH, Carcaboso AM, Bugiani M, Phoenix TN, van Tellingen O, van Vuurden DG, Kaspers GJL and Hulleman E.
Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma
CLINICAL CANCER RESEARCH . 26(13): 3319-3332. Nº de cites: 42
-
Pinto EM, Figueiredo BC, Chen W, Galvao HCR, Formiga MN, Fragoso MCBV, Ashton-Prolla P, Ribeiro EMSF, Felix G, Costa TEB, Savage SA, Yeager M, Palmero EI, Volc S, Salvador-Hernandez H, Fuster-Soler JL, Lavarino C, Chantada G, Vaur D, Odone-Filho V, Brugières L, Else T, Stoffel EM, Maxwell KN, Achatz MI, Kowalski L, de Andrade KC, Pappo A, Letouze E, Latronico AC, Mendonca BB, Almeida MQ, Brondani VB, Bittar CM, Soares EWS, Mathias C, Ramos CRN, Machado M, Zhou W, Jones K, Vogt A, Klincha PP, Santiago KM, Komechen H, Paraizo MM, Parise IZS, Hamilton KV, Wang J, Rampersaud E, Clay MR, Murphy AJ, Lalli E, Nichols KE, Ribeiro RC, Rodriguez-Galindo C, Korbonits M, Zhang J, Thomas MG, Connelly JP, Pruett-Miller S, Diekmann Y, Neale G, Wu G and Zambetti GP.
XAF1 as a modifier of p53 function and cancer susceptibility.
Science Advances . 6(26): . Nº de cites: 39
-
Deligne C, Hachani J, Duban-Deweer S, Meignan S, Leblond P, Carcaboso AM, Sano Y, Shimizu F, Kanda T, Gosselet F, Dehouck MP and Mysiorek C.
Development of a human in vitro blood-brain tumor barrier model of diffuse intrinsic pontine glioma to better understand the chemoresistance
Fluids and Barriers of the CNS . 17(1): 37-37. Nº de cites: 32
-
Galardi A, Colletti M, Lavarello C, Paolo VD, Mascio P, Russo I, Cozza R, Romanzo A, Valente P, Vito R, Pascucci L, Peinado H, Carcaboso AM, Petretto A, Locatelli F and Giannatale AD.
Proteomic Profiling of Retinoblastoma-Derived Exosomes Reveals Potential Biomarkers of Vitreous Seeding
Cancers . 12(6): . Nº de cites: 35
-
Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennett J, Alderete D, Balaguer Guill J, Baroni L, Bartels U, Bavle A, Bornhorst M, Boue DR, Canete A, Chintagumpala M, Coven SL, Cruz-Martínez O, Dahiya S, Dirks P, Dunkel IJ, Eisenstat D, Faure Conter C, Finch E, Finlay JL, Frappaz D, Garre ML, Gauvain K, Bechensteen AG, Hansford JR, Harting I, Hauser P, Hazrati LN, Huang A, Injac SG, Iurilli V, Karajannis M, Kaur G, Kyncl M, Krskova L, Laperriere N, Larouche V, Lassaletta A, Leary S, Lin F, Mascelli S, McKeown T, Milde T, Morales-La Madrid A, Morana G, Morse H, Mushtaq N, Osorio DS, Packer R, Pavelka Z, Quiroga-Cantero E, Rutka J, Sabel M, Salgado D, Solano P, Sterba J, Su J, Sumerauer D, Taylor MD, Toledano H, Tsang DS, Valente Fernandes M, van Landeghem F, van Tilburg CM, Wilson B, Witt O, Zamecnik J, Bouffet E, Hawkins C and Tabori U.
Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition
JCO Precision Oncology . 4: 561-571. Nº de cites: 90